Drug company Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) completed the placing of 5,918,000 shares to at least six investors at HK$331.8 apiece to raise net proceeds of a little over HK$1.94 billion, a Thursday Hong Kong bourse filing said.
Proceeds will be used for the R&D, trials, registration, manufacturing, and commercialization of products; external collaborations; product pipeline portfolio expansion; and replenishment of working capital among other uses.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.